Insmed Inc at Nasdaq Investor Conference Transcript
It is our next speaker Rodger Adsett, Chief Operating Officer of Insmed. Roger.
Great. Good morning everyone. Thank you very much. My name is Roger Adsett. I'm the chief operating officer at Insmed and I'm very pleased to be here today representing the company.
Let me remind you that today's presentation will include Forward-looking statements and please refer to our filings for the SEC, which are available through the SEC website. Insmed is a global biopharmaceutical company with a focus on helping patients with serious and rare diseases. We look to make a meaningful impact on the lives of patients through our medicines.
We focused on four key strategic priorities for 2019, first continued execution of the U.S. launch of Arikayce. Our first commercial product, Arikayce was approved in September 2018 for the treatment of refractory mycobacterium avium complex or MAC, lung disease in adult patients with limited or no treatment options. Our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
